- Home
- CATY vs BCTXW Comparison
CATY vs BCTXW Comparison
Compare CATY & BCTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATY
- BCTXW
- Stock Information
- Founded
- CATY 1962
- BCTXW N/A
- Country
- CATY United States
- BCTXW Canada
- Employees
- CATY N/A
- BCTXW 12
- Industry
- CATY Major Banks
- BCTXW Biotechnology: Pharmaceutical Preparations
- Sector
- CATY Finance
- BCTXW Health Care
- Exchange
- CATY Nasdaq
- BCTXW Nasdaq
- Market Cap
- CATY N/A
- BCTXW N/A
- IPO Year
- CATY N/A
- BCTXW N/A
- Fundamental
- Price
- CATY $47.49
- BCTXW $0.28
- Analyst Decision
- CATY Hold
- BCTXW
- Analyst Count
- CATY 4
- BCTXW 0
- Target Price
- CATY $47.75
- BCTXW N/A
- AVG Volume (30 Days)
- CATY 404.1K
- BCTXW N/A
- Earning Date
- CATY 01-22-2025
- BCTXW N/A
- Dividend Yield
- CATY 2.86%
- BCTXW N/A
- EPS Growth
- CATY N/A
- BCTXW N/A
- EPS
- CATY 3.96
- BCTXW N/A
- Revenue
- CATY $723,750,000.00
- BCTXW N/A
- Revenue This Year
- CATY N/A
- BCTXW N/A
- Revenue Next Year
- CATY $4.76
- BCTXW N/A
- P/E Ratio
- CATY $11.99
- BCTXW N/A
- Revenue Growth
- CATY N/A
- BCTXW N/A
- 52 Week Low
- CATY $33.88
- BCTXW N/A
- 52 Week High
- CATY $55.29
- BCTXW N/A
- Technical
- Relative Strength Index (RSI)
- CATY 36.58
- BCTXW N/A
- Support Level
- CATY $46.90
- BCTXW N/A
- Resistance Level
- CATY $51.10
- BCTXW N/A
- Average True Range (ATR)
- CATY 1.41
- BCTXW 0.00
- MACD
- CATY -0.68
- BCTXW 0.00
- Stochastic Oscillator
- CATY 15.66
- BCTXW 0.00
About BCTXW BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.